A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
about
The epigenetic basis of diffuse large B-cell lymphomaB cells in chronic graft-versus-host diseaseCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewA Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In VivoThe structure of the Bach2 POZ-domain dimer reveals an intersubunit disulfide bondThe ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domainA purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.BCL6 is critical for the development of a diverse primary B cell repertoire.Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells.DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas.The transcriptional modulator BCL6 as a molecular target for breast cancer therapyBCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapyFingerprinting acute leukemia: DNA methylation profiling of B-acute lymphoblastic leukemia.Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?Ex vivo engineered immune organoids for controlled germinal center reactions.Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell LymphomaNAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells.Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?Novel peptide isomer strategy for stable inhibition of catecholamine release: application to hypertensionLMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibitionLineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanismsThe BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivoIkaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemiaNuclear hormone receptor co-repressors: structure and function.Strategies for identifying synthetic peptides to act as inhibitors of NADPH oxidases, or "all that you did and did not want to know about Nox inhibitory peptides".New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis.Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia.
P2860
Q26852288-02D270CD-4D86-4790-858E-8DDFD5759977Q26861706-C8D1C9D4-48E5-47F8-8DB1-F2464E0F41A2Q27025242-212CD32C-F165-46C4-A7DA-B1C8F80F9970Q27304386-E7DC03B1-FD81-4546-A288-9568F861A00BQ27660498-7A388279-62B0-427D-904F-F307DFD0CB51Q27676372-22DE000B-80F0-4D93-9A08-C5890DA65D0BQ27681982-E648CA48-56BC-4FCD-BE08-234B2900B0D2Q33588432-A523122F-500A-4005-A4C5-8F9422AFD836Q33834752-F12FAC33-F3F9-4B3F-9EF9-21C196C4C14AQ33902336-AE3DCC0D-EEE5-4083-8322-0B54AA3E8DDCQ33977987-FD8FC095-721E-4DA3-A095-112E338E8A30Q34096524-CAFDA4BB-A043-41A2-BFF2-36C9286F95CFQ34245186-F97A573A-FF5E-4447-8651-DD43D4FBA1C7Q34360164-0893DFBD-2673-44D0-A93E-9C4544369E2AQ35017525-25192F96-5BA4-444C-8890-321DE031F739Q35063947-A21CCFAF-EEBB-4D2E-828E-62F0449CECF4Q35441406-3990C996-D383-4F46-859D-5390767EED96Q35687836-E323FBE8-CAC2-415B-9417-9915A45EC3D8Q35812007-5CCE4999-FE1C-4958-86F7-F3D1553DF83AQ35931271-3CDCE126-9532-4D73-A886-67D8B968D91BQ36042686-1030C5E6-0866-4BBC-B0EB-A21F96004543Q36170245-6BF7043A-C91C-4611-8C59-3A71EA5F1302Q36201677-9AA8EA1A-2310-4191-961A-142A7E69529FQ36363291-903D7A2F-C464-428B-89F4-F470D9AE4CC3Q36470847-8419633F-1322-473C-B1A6-10051616BF14Q36481117-BC125BE9-81C9-4B1D-A5E4-4062963DF346Q36684951-EE879556-DA36-4512-ADF4-3AB33B3D183BQ36703936-C185EAD7-21C8-45FF-9351-3B3E8BE5741AQ37209061-CFAAFC8E-33DC-4537-A8B5-78F4EBC0B817Q37504931-0A10735B-1E90-4DC6-BF25-F505B6B33113Q37554700-F769F101-39AE-4E6B-AE1F-EADA6FD39EDFQ37699271-BD01C09F-290E-40E7-88A1-2591C7EE0E98Q37702652-6956B4F2-7A28-4A5D-8575-D7701A133D5CQ37934059-6D37B1A5-A097-4F82-8836-E3FA2BA5B0FFQ38007895-DBE21251-BBCE-43BB-838F-A9191FB1029EQ38110970-745949EC-0607-4F4E-98FE-70BCA4D267C0Q38161760-ED3DEF14-8591-4FA7-80B5-4A3FC3F51996Q38179500-D784C9EA-722E-46F1-A534-87D980BBD68FQ38201872-771EFAEF-EBBE-4A78-8DB9-5D55624E6461Q38289046-3F2DE3D6-7E44-4268-AA27-E69F1D264BD5
P2860
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
@en
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
@nl
type
label
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
@en
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
@nl
prefLabel
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
@en
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
@nl
P2093
P2860
P1433
P1476
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
@en
P2093
Amy Chadburn
Ari Melnick
Katerina Hatzi
Rita Shaknovich
Shao Ning Yang
Steven F Dowdy
P2860
P304
P356
10.1182/BLOOD-2008-07-168773
P407
P577
2008-10-16T00:00:00Z